Sage Therapeutics Inc (SAGE)

Add to Watchlists
Create an Alert
139.50 -1.41  -1.00% NASDAQ Oct 22, 15:47 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/19/2020 08:00 EST Misc Sage Therapeutics Inc Fourth Quarter Earnings Conference Call in 2019
02/19/2020 Earnings Sage Therapeutics Inc Fourth Quarter Earnings in 2019 Release
11/12/2019 08:00 EST Misc Sage Therapeutics Inc Third Quarter Earnings Conference Call for 2019
11/12/2019 Earnings Sage Therapeutics Inc Third Quarter Earnings in 2019 Release
08/06/2019 08:00 EDT Misc Sage Therapeutics Inc Second Quarter Earnings Conference Call in 2019
08/06/2019 Earnings Sage Therapeutics Inc Second Quarter Earnings in 2019 Release
06/05/2019 09:00 EDT Misc Sage Therapeutics Inc Annual General Meeting in 2018
05/02/2019 08:00 EDT Misc Sage Therapeutics Inc First Quarter Earnings Conference Call in 2019
05/02/2019 Earnings Sage Therapeutics Inc First Quarter Earnings in 2019 Release
02/19/2019 08:00 EST Misc Sage Therapeutics Inc Fourth Quarter Earnings Conference Call in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.sagerx.com
  • Investor Relations URL: http://investor.sagerx.com/
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Nov. 12, 2019
  • Last Earnings Release: Aug. 06, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.

Top Fund Holders

Symbol Name Weighting
ETCGX Eventide Gilead C 2.97%
BTEC Principal Healthcare Innovators ETF 2.26%
FBIOX Fidelity® Select Biotechnology 2.25%
THISX T. Rowe Price Health Sciences I 2.14%
HQL Tekla Life Sciences Investors 1.22%
HFMRX Hartford MidCap R3 1.17%
FCGSX Fidelity® Series Growth Company 1.08%
HQH Tekla Healthcare Investors 1.07%
IBB iShares Nasdaq Biotechnology ETF 1.05%
UBIO ProShares UltraPro Nasdaq Biotechnology 0.95%
FGCKX Fidelity® Growth Company K 0.94%
IEIH iShares Evolved US Innvtv Hlthcare ETF 0.64%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.